Evidence map›Paper›PMID 35879032›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2022

Inhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder: A Prospective Study on the Effects of Time.

Marc Ferrer, Óscar Soto-Angona, María Soler-Artigas, Pol Ibáñez, Christian Fadeuilhe, Raúl Felipe Palma-Álvarez, Raquefet Lidai, Sebastian Vargas-Cáceres, María Ángeles Torrecilla, Anna López and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Prescription Patterns of Intramuscular Medication for Psychomotor Agitation: A Survey of Italian Psychiatrists.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Marc FerrerDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-1283-8578
Óscar Soto-AngonaDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0003-0234-4280
María Soler-ArtigasBiomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-3213-1107
Pol IbáñezGroup of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.ORCID https://orcid.org/0000-0003-0714-8908
Christian FadeuilheDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0001-5821-347X
Raúl Felipe Palma-ÁlvarezDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0002-6428-9865
Raquefet LidaiDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0003-4476-1226
Sebastian Vargas-CáceresDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0001-6113-0392
María Ángeles TorrecillaDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0001-5811-2695
Anna LópezDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0003-3932-9674
Josep Antoni Ramos-QuirogaDepartment of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0003-1622-0350
Vall d'Hebron Hospital Universitari · ESUniversitat Autònoma de Barcelona · ESCentro de Investigación Biomédica en Red de Salud Mental · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Agitation in patients diagnosed with personality disorders (PD) is one of the most frequent crises in emergency departments (ED). Although many medications have been tested, their effectiveness has been small or non-significant, and no specific drugs are supported by the available evidence. This study aimed to evaluate the efficacy of Inhaled loxapine (IL) as a therapeutic option for agitated patients with PD. Methods: A naturalistic, unicentric, prospective study was carried out. Thirty subjects diagnosed with PD and attending the ED with episodes of agitation were recruited most of whom were women diagnosed with Borderline Personality Disorder. Subjects were treated with a single dose of IL (9.1 mg). Efficacy was assessed with the Clinical Global Impression scale, the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) and the Agitation-Calmness Evaluation Scale (ACES). Patients were followed 60 minutes after administration to measure IL effect and its duration. Results: IL exhibited an overall efficacy in managing mild to severe agitation, with a quick onset of effect and persistence. 'Effect of time', where IL efficacy is maintained over time, is more marked in higher-severity agitation. No additional treatments were needed to improve agitation during the follow-up time. Conclusion: Results suggest that IL could be a safe and effective option to manage agitation in PD.

Indexed as

Antipsychotic agentsLoxapinePersonality disordersPsychomotor agitation

Identifiers

PMID35879032
PMCPMC9329112
OpenAlexW4287831420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.